Why Farbe Firma is the Top Manufacturer of Etoricoxib Injection
- Maulik Sudani
- 8 hours ago
- 8 min read
Last Updated: June 28, 2026
TL;DR: Etoricoxib Injection - a sterile, ready-to-use aqueous solution of etoricoxib, one of the most COX-2 selective of the coxib NSAIDs, supplied commonly as a 60 mg/2 mL ampoule (30 mg/mL) given by deep intramuscular injection - is the strong, non-opioid analgesic and anti-inflammatory clinicians use for the short-term control of acute pain and the painful flares of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gout, where high COX-2 selectivity spares platelet function and the gastric mucosa relative to traditional non-selective NSAIDs. Because etoricoxib is a poorly water-soluble weak base that has to be solubilised and held in solution at a tightly controlled pH, each ampoule must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the related-substance profile, the controlled pH that keeps the active in solution, clarity, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Etoricoxib Injection at our Gujarat, India facility and supplies it to surgical, anaesthesia, pain-management, rheumatology and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Highly selective COX-2 inhibitor (coxib) NSAID - etoricoxib preferentially blocks cyclo-oxygenase-2 to control pain and inflammation while largely sparing platelet aggregation and the gastric mucosa relative to traditional non-selective NSAIDs, and Etoricoxib Injection (60 mg/2 mL, deep intramuscular) demands an exact, reproducible parenteral dose for the short-term management of acute pain and inflammatory flares.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated light-protected compounding and ampoule filling lines, control of the stability-indicating assay, the related-substance profile, the tightly controlled pH that holds the poorly soluble active in solution, clarity, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Etoricoxib Injection Demands a Premium Manufacturer
Etoricoxib Injection occupies a useful place in modern pain and inflammation management across every market. It is the analgesic a clinician reaches for when a patient needs strong, non-opioid relief from acute pain or an inflammatory flare but cannot conveniently take a tablet - in the early hours after surgery, in an acute gout attack, or during a severe exacerbation of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis. What makes etoricoxib distinctive is its selectivity: it is one of the most COX-2 selective of all the coxibs, blocking the cyclo-oxygenase-2 enzyme that drives pain and inflammation while having very little effect on cyclo-oxygenase-1, the enzyme that protects the stomach lining and supports normal platelet function. That selectivity is why a coxib is valued as part of a multimodal, opioid-sparing regimen in patients for whom preserving clotting and gastric tolerance matters. Because the injection is given parenterally, the dose from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Etoricoxib Injection is presented as a ready-to-use sterile solution - for example 60 mg of etoricoxib in a 2 mL ampoule, 30 mg/mL, given by deep intramuscular injection - so the assay must be exact and the fill volume accurate so that each unit delivers the labelled content. The formulation challenge is solubility: etoricoxib is a poorly water-soluble weak base, most soluble in a controlled, slightly acidic environment, so the solution is compounded and held at a tightly controlled pH that keeps the active fully in solution from filling through to the end of shelf life, with no risk of precipitation in the ampoule. The solution must stay clear, free of visible and sub-visible particulates and low in endotoxin, and the manufacturer must run a stability-indicating method that resolves and quantifies etoricoxib and its related substances without interference. Etoricoxib is light-sensitive, so photostability under ICH Q1B and light-protective processing and packaging matter, and the right sterilisation route - terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing - must be selected and validated. The coxib class cautions - the cardiovascular thrombotic risk, the dose-related rise in blood pressure that makes uncontrolled hypertension a contraindication, the contraindication after coronary artery bypass graft (CABG) surgery, the risk of serious skin reactions and the gastrointestinal and renal cautions of the NSAID class - must be clearly carried on the label. Choosing an Etoricoxib Injection manufacturer that treats the stability-indicating assay, related-substance control, the controlled pH that maintains solubility, photostability, clarity and particulate and endotoxin control as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Etoricoxib Injection Manufacturer Apart
A world-class manufacturer of Etoricoxib Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of etoricoxib with related-substance control by validated HPLC, which a potent selective NSAID demands; a robust, validated sterilisation and fill process built around a controlled-pH solubilised solution that must stay clear and precipitate-free from compounding through to the point of use; and tender-ready dossier support, including photostability and accelerated stability data, for an analgesic procured through hospital-pharmacy and ministry-of-health channels. It starts with the active - pharmacopoeial- or in-house-specification-grade etoricoxib sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the clarity and the solubility of a poorly water-soluble active. The bulk solution is compounded in water-for-injection at the tightly controlled pH that holds etoricoxib in solution, sterile-filtered through a 0.22 micron membrane and filled into ampoules - or vials - under ISO Class 5 conditions and under light protection, with the validated sterilisation route locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of etoricoxib by validated HPLC, the related-substance profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intramuscular administration. Because the active is poorly soluble and light-sensitive, assay accuracy, related-substance control, pH control and photostability are confirmed together so the assay and clarity stay within specification across shelf life, with no precipitation in the ampoule.
Quality Systems Behind Every Etoricoxib Injection
Every Farbe Firma Etoricoxib Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of etoricoxib against reference standards, control of related substances by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated filling lines with 100 % inspection, light-protected compounding and holding, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because etoricoxib is a poorly soluble, light-sensitive selective NSAID given parenterally and the assay, related-substance profile, controlled pH and photostability drive both efficacy and safety, we treat the stability-indicating assay, the related-substance profile, the solubility-maintaining pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated (40 degrees C / 75 % RH) conditions, with ICH Q1B photostability documented, so the assay, clarity and colour stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Etoricoxib Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad analgesia, anti-inflammatory and peri-operative small-volume parenteral portfolio. For Etoricoxib Injection specifically, we supply the ready-to-use 60 mg/2 mL solution in ampoule and vial presentations under WHO-GMP conditions, with country-specific strengths (including 30 mg), fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the stability-indicating-assay, related-substance, pH, photostability, sterilisation and container-closure data package - ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, stability-indicating method-validation data, sterilisation and container-closure reports, translated package inserts and artwork - including deep-intramuscular administration instructions, store-below-25-degrees-C and protect-from-light storage directions, and the cardiovascular, uncontrolled-hypertension, post-CABG, serious-skin-reaction and gastrointestinal-and-renal cautions - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Etoricoxib Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through API sourcing, the development of a stability-indicating assay for a selective coxib, related-substance control, controlled-pH solubilised-solution formulation design, photostability strategy, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a highly selective COX-2 inhibitor where dose precision, solubility control and clarity directly govern patient safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Etoricoxib Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Etoricoxib Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated light-protected compounding and ampoule filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Etoricoxib Injection do you supply?
Our standard presentation is the ready-to-use 60 mg/2 mL (30 mg/mL) solution of etoricoxib in an ampoule for deep intramuscular injection; a 30 mg presentation is also available. Custom strengths, fill configurations, ampoule and vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Etoricoxib Injection mainly used for?
Etoricoxib Injection is used for the short-term management of acute pain and the painful flares of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gout. It is one of the most COX-2 selective coxibs, sparing platelets and the gastric mucosa relative to traditional non-selective NSAIDs; Farbe Firma verifies the assay, related-substance profile, pH, clarity, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose. It is given by deep intramuscular injection, and the cardiovascular, uncontrolled-hypertension, post-CABG and serious-skin-reaction cautions of the class are carried on the label.
Can Farbe Firma support country-specific registrations for Etoricoxib Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, stability-indicating method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Etoricoxib Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our analgesia and anti-inflammatory small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments